{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:29:55Z","timestamp":1775140195875,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jaac.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T13:26:05Z","timestamp":1408109165000},"page":"1092-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Response\/Remission With Guanfacine Extended-Release and Psychostimulants in\u00a0Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1016","volume":"53","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Brams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Bukstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"McBurnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2014.08.001_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of\u00a0children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(05)66915-2","article-title":"Attention-deficit hyperactivity disorder","volume":"366","author":"Biederman","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2014.08.001_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib4","first-page":"17","article-title":"Pharmacotherapy for attention-deficit-hyperactivity disorder","volume":"2","author":"Faraone","year":"2009","journal-title":"US Psychiatry Rev"},{"key":"10.1016\/j.jaac.2014.08.001_bib5","series-title":"Attention deficit hyperactivity disorder among children aged 5-17 years in the United States, 1998-2009. NCHS data brief, No 70","author":"Akinbami","year":"2011"},{"key":"10.1016\/j.jaac.2014.08.001_bib6","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR)","first-page":"85","article-title":"American Psychiatric Association. Attention-deficit and disruptive behavior disorders","year":"2000"},{"key":"10.1016\/j.jaac.2014.08.001_bib7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00004583-199608000-00008","article-title":"Attention deficit disorder: a review of the past 10\u00a0years","volume":"35","author":"Cantwell","year":"1996","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"4 Suppl","key":"10.1016\/j.jaac.2014.08.001_bib8","first-page":"S117","article-title":"New options in the pharmacological management of attention-deficit\/hyperactivity disorder","volume":"10","author":"Olfson","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaac.2014.08.001_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM199903113401007","article-title":"Treatment of attention-deficit-hyperactivity disorder","volume":"340","author":"Elia","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2014.08.001_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1087054707305968","article-title":"Beyond methylphenidate: nonstimulant medications for youth with ADHD","volume":"11","author":"Wood","year":"2007","journal-title":"J\u00a0Atten Disord"},{"key":"10.1016\/j.jaac.2014.08.001_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A\u00a0placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jaac.2014.08.001_bib12","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1136\/adc.2004.059352","article-title":"Managing attention deficit\/hyperactivity disorder: unmet needs and future directions","volume":"90","author":"Steer","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaac.2014.08.001_bib13","first-page":"402","article-title":"Attention deficit\/hyperactivity disorder (ADHD) in children: rationale for its integrative management","volume":"5","author":"Kidd","year":"2000","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.jaac.2014.08.001_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11920-006-0044-9","article-title":"Combination pharmacotherapy for adult ADHD","volume":"8","author":"Adler","year":"2006","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaac.2014.08.001_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pedhc.2010.10.001","article-title":"Attention deficit hyperactivity disorder: part III","volume":"25","author":"Ryan-Krause","year":"2011","journal-title":"J\u00a0Pediatr Health Care"},{"key":"10.1016\/j.jaac.2014.08.001_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1472-6963-9-95","article-title":"A\u00a0retrospective claims analysis of combination therapy in the treatment of adult attention-deficit\/hyperactivity disorder (ADHD)","volume":"9","author":"Pohl","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jaac.2014.08.001_bib17","series-title":"INTUNIV (guanfacine) extended-release tablets [package insert]","year":"2013"},{"key":"10.1016\/j.jaac.2014.08.001_bib18","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2014.08.001_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial","volume":"48","author":"Sallee","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib20","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaac.2014.08.001_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/cap.2010.0064","article-title":"Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit\/hyperactivity disorder","volume":"21","author":"Kollins","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.08.001_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2008.0152","article-title":"Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Spencer","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.08.001_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","article-title":"Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Sallee","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.08.001_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaac.2011.10.012","article-title":"A\u00a0controlled trial of extended-release guanfacine and psychostimulants for attention-deficit\/hyperactivity disorder","volume":"51","author":"Wilens","year":"2012","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib25","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.clinthera.2006.11.006","article-title":"Remission versus response as the goal of therapy in ADHD: a new standard for the field?","volume":"28","author":"Steele","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaac.2014.08.001_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1017\/S1092852900000535","article-title":"Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit\/hyperactivity disorder","volume":"15","author":"Findling","year":"2010","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.jaac.2014.08.001_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11538450-000000000-00000","article-title":"Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder","volume":"25","author":"Ramos-Quiroga","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaac.2014.08.001_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1469-7610.2008.01960.x","article-title":"Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo","volume":"50","author":"Buitelaar","year":"2009","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.clinthera.2006.11.007","article-title":"Measurable outcomes in psychiatric disorders: remission as a marker of wellness","volume":"28","author":"McIntyre","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaac.2014.08.001_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.157.5.816","article-title":"Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type","volume":"157","author":"Biederman","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib31","series-title":"ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"1998"},{"key":"10.1016\/j.jaac.2014.08.001_bib32","unstructured":"Ginsberg LD, Jain R, Murphy WR, Lyne A, Rubin J, Youcha S. Response and symptomatic remission with open-label coadministration of guanfacine extended release and stimulants for ADHD. Poster presented at the 163rd Annual Meeting of the American Psychiatric Association, May 22-26, 2010, New Orleans, LA."},{"key":"10.1016\/j.jaac.2014.08.001_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0924-977X(03)00047-6","article-title":"Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention","volume":"13","author":"Buitelaar","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2014.08.001_bib34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/brain\/awn116","article-title":"Placebo effects: clinical aspects and neurobiology","volume":"131","author":"Oken","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jaac.2014.08.001_bib35","first-page":"122","article-title":"Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit\/hyperactivity disorder","volume":"10","author":"Perwien","year":"2004","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.jaac.2014.08.001_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00787-008-0725-5","article-title":"Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents","volume":"18","author":"Svanborg","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","article-title":"Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study","volume":"48","author":"Newcorn","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib38","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1542\/peds.2010-1260","article-title":"Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD","volume":"127","author":"Kollins","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2014.08.001_bib39","first-page":"44","article-title":"Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD","volume":"17","author":"Goodman","year":"2010","journal-title":"Primary Psychiatry"},{"key":"10.1016\/j.jaac.2014.08.001_bib40","unstructured":"Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD: results from a phase III multicenter trial. J Atten Disord. (in press)."},{"key":"10.1016\/j.jaac.2014.08.001_bib41","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1542\/peds.112.5.e404","article-title":"A\u00a0dose-response study of OROS methylphenidate in children with attention-deficit\/hyperactivity disorder","volume":"112","author":"Stein","year":"2003","journal-title":"Pediatrics"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856714005310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856714005310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:23:55Z","timestamp":1760192635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856714005310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0890856714005310"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2014.08.001","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response\/Remission With Guanfacine Extended-Release and Psychostimulants in\u00a0Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2014.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}